首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1736672

2026 年至 2032 年肝癌治療市場（按流程、類型、最終用戶和地區分類）

Liver Cancer Treatment Market by Process (Targeted Therapy, Chemotherapy), Type (Hepatocellular Carcinoma, Cholangio Carcinoma), End-User (Hospitals, Clinics), & Region for 2026-2032

出版日期: 2025年05月06日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

肝癌治療市場評估-2026-2032

人們對早期診斷的認知不斷提高，加上成像技術的進步，推動了肝癌治療市場規模的成長。根據 Verified Market Research 分析師預測，肝癌治療市場規模預計在 2024 年將達到約 354 萬美元，到 2032 年將達到 888 萬美元。

肝癌治療市場的快速擴張主要歸因於旨在改善治療方案和提高患者預後的研發活動投資的增加，預計從 2026 年到 2032 年，複合年成長率將達到 13.45%。

肝癌治療市場：定義/概述

肝癌治療是指一系列旨在控制肝癌的醫療干預措施，包括手術、化療、標靶治療和免疫療法等多種治療方法。早期發現和個人化治療方案的重要性已被強調，以改善患者的預後和存活率。治療方法的選擇是基於癌症的分期、患者的一般狀況和具體的腫瘤特徵，以確保個人化的治療方案。

對新型治療藥物研發和技術進步的日益重視被認為是肝癌治療市場的主要成長要素。此外，由於肝炎感染和飲酒等因素導致的肝癌發生率上升也被認為是推動市場擴張的關鍵因素。隨著人們對肝癌及其治療方法的認知不斷提高，研發投資也成為優先事項，這進一步推動了市場的成長。

加大研發投入將對肝癌治療市場產生什麼影響？

肝癌治療市場不斷增加的研發投入已產生顯著影響。這些投入主要用於研發和臨床試驗新型治療藥物，可望提升療效和患者預後。標靶治療和免疫療法也因此取得了突破，促進了整體市場的成長。

根據美國國家癌症研究所 (NCI) 的數據，美國癌症相關總支出預計將從 2015 年的 1,830 億美元增加到 2030 年的 2,460 億美元，其中很大一部分將用於研發工作。

此外，製藥公司與研究機構之間的合作正在加速，以加快開發進程，預計將為患者帶來更廣泛的治療選擇。這種對技術創新的關注被認為對於滿足肝癌患者尚未滿足的醫療需求至關重要，也是市場擴張的驅動力。

日益增加的監管挑戰如何影響肝癌治療市場的成長？

日益嚴峻的監管挑戰正顯著影響肝癌治療市場的成長。遵守監管機構嚴格的核准流程可能會延遲新治療方法的上市。此外，由於需要進行大量的臨床試驗並遵守安全標準，這需要耗費大量的時間和財力，因此這些挑戰更加嚴峻。

因此，企業被迫加大對監管策略和上市計畫的投資，以有效規避這些障礙。整個行業都感受到了這種影響，因為這些監管障礙可能會扼殺創新，並延緩可能挽救生命的療法的商業化。

Increasing awareness regarding early diagnosis and advancements in imaging technologies have been driving the growth of the liver cancer treatment market size. According to the analyst from Verified Market Research, the Liver Cancer Treatment Market is estimated to reach a valuation of USD 8.88 Million By 2032 over the forecast subjugating around USD 3.54 Million valued in 2024.

The rapid expansion of the liver cancer treatment market is primarily driven by increasing investments in research and development activities aimed at improving therapeutic options and enhancing patient outcomes. It enables the market to grow at a CAGR of 13.45% from 2026 to 2032.

Liver Cancer Treatment Market: Definition/ Overview

Liver cancer treatment is defined as a range of medical interventions aimed at managing liver cancer, which includes various therapies such as surgery, chemotherapy, targeted therapy, and immunotherapy. The significance of early detection and tailored treatment plans has been emphasized in improving patient outcomes and survival rates. Treatments are utilized based on the stage of cancer, the overall health of the patient, and specific tumor characteristics, ensuring a personalized approach to care.

Increasing focus on the development of novel therapeutic agents and advancements in technology are being recognized as key growth factors in the liver cancer treatment market. The rising prevalence of liver cancer, driven by factors such as hepatitis infections and alcohol consumption, has also been acknowledged as a crucial element contributing to market expansion. As awareness regarding liver cancer and its treatment options continues to grow, investments in research and development are being prioritized, further supporting market progression.

What Impact is Being Observed from the Rising Investments in Research and Development on the Liver Cancer Treatment Market?

A significant impact is being observed from the rising investments in research and development on the liver cancer treatment market. These investments are being directed toward the discovery and clinical testing of novel therapeutic agents, which are expected to enhance treatment efficacy and patient outcomes. As a result, breakthroughs in targeted therapies and immunotherapies are being achieved, contributing to the overall growth of the market.

According to the National Cancer Institute (NCI), the total national cancer-related expenditure in the United States is projected to increase from USD 183 Billion in 2015 to USD 246 Billion in 2030, a substantial portion of which is dedicated to research and development efforts.

Furthermore, collaborations between pharmaceutical companies and research institutions are being established to accelerate the development process, which is anticipated to result in a wider range of treatment options for patients. This focus on innovation is being recognized as essential in addressing the unmet medical needs of liver cancer patients, thereby driving market expansion.

How are Increasing Regulatory Challenges Affecting the Growth of the Liver Cancer Treatment Market?

Increasing regulatory challenges are affecting the growth of the liver cancer treatment market significantly. Stringent approval processes imposed by regulatory bodies are being observed, which can lead to delays in the introduction of new therapies into the market. These challenges are compounded by the need for extensive clinical trials and compliance with safety standards, which require substantial time and financial resources.

As a result, companies are being encouraged to invest more in regulatory strategies and market access planning to navigate these obstacles effectively. The overall impact of these regulatory hurdles is being felt across the industry, as they can inhibit innovation and slow down the commercialization of potentially life-saving treatments.

Category-Wise Acumens

What Factors are Contributing to the Dominance of Targeted Therapy in the Liver Cancer Treatment Market?

According to VMR analyst, several factors are contributing to the dominance of targeted therapy in the liver cancer treatment market. The specificity of targeted therapies, which focus on particular molecular targets associated with cancer cells, is being recognized for its ability to minimize damage to healthy tissues, leading to fewer side effects compared to traditional treatments. Additionally, significant advancements in molecular diagnostics have enabled the identification of patients who are most likely to benefit from these therapies.

The increasing prevalence of liver cancer, particularly among high-risk populations, is also being acknowledged as a driving force behind the demand for targeted treatment options. Moreover, partnerships between pharmaceutical companies and biotechnology firms are being formed to accelerate the development and commercialization of innovative targeted therapies, further solidifying this segment's leading position in the market.

What are the Key Trends Driving the Rapid Growth of Hepatocellular Carcinoma Treatments?

According to VMR Analyst, key trends driving the rapid growth of hepatocellular carcinoma treatments are being observed as the focus on early detection and improved treatment methodologies continues to increase. The rising incidence of hepatocellular carcinoma, fueled by factors such as chronic hepatitis infections and non-alcoholic fatty liver disease, is being recognized as a critical factor for market expansion. Innovative treatment options, including combination therapies that utilize both targeted agents and immunotherapy, are being developed to enhance treatment efficacy.

Furthermore, growing awareness of liver cancer symptoms and risk factors among healthcare professionals and patients is being emphasized, resulting in earlier diagnoses and timely interventions. The overall impact of these trends is anticipated to lead to a substantial increase in the adoption of hepatocellular carcinoma treatments, contributing significantly to the growth of the liver cancer treatment market.

Country/Region-wise Acumens

What are the Key Factors Contributing to the Dominance of North America in the Liver Cancer Treatment Market?

According to VMR Analyst, the dominance of North America in the liver cancer treatment market is being attributed to several key factors. Advanced healthcare infrastructure and a high level of investment in research and development are being recognized as significant contributors to the region's market leadership. Additionally, the presence of major pharmaceutical companies and biotechnology firms has facilitated the rapid development and commercialization of innovative treatment options. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), the U.S. biopharmaceutical industry invested an estimated USD 91 Billion in R&D in 2020.

Strong government support for cancer research, along with favorable reimbursement policies for liver cancer treatments, is also being acknowledged as a crucial factor driving market growth. Furthermore, increasing awareness of liver cancer and its treatment options among healthcare providers and patients is being emphasized, leading to higher diagnosis rates and subsequently greater demand for treatment.

How is the Rising Incidence of Liver Cancer in the Asia Pacific Region Impacting the Growth of the Market?

According to VMR Analyst, the rising incidence of liver cancer in the Asia Pacific region is impacting the growth of the liver cancer treatment market significantly. A surge in risk factors, such as chronic hepatitis B and C infections and increasing alcohol consumption, is being observed, contributing to a higher prevalence of the disease in this area. According to the World Health Organization's GLOBOCAN 2020 data, Eastern Asia accounted for about 55.8% of new liver cancer cases globally in 2020. China alone contributed to nearly half of the global liver cancer burden, with an estimated 410,038 new cases in 2020.

The demand for effective treatment options is being fueled by an increasing population and expanding healthcare access in countries such as China and India. Moreover, governmental initiatives aimed at improving cancer care and early detection programs are being implemented, which are expected to enhance treatment rates. As a result, investments in the development of innovative therapies tailored for the unique needs of this region are being prioritized, further driving the market's expansion in Asia Pacific.

Competitive Landscape

The Liver Cancer Treatment Market's competitive landscape is characterized by a varied range of companies, including technology developers, plant operators, and service providers, all striving for market share in an increasingly dynamic and growing industry.

Some of the prominent players operating in the liver cancer treatment market include:

Bayer AG

Bristol-Myers Squibb Company

Eisai Co. Ltd.

Elli Lilly and Company

Exelixis, Inc.

Merck & Co., Inc.

Novartis AG

Pfizer, Inc.

Liver Cancer Treatment Market Recent Developments

In January 2021, F. Hoffmann-La Roche Ltd. reported updated overall survival statistics from the Phase III Mbrave150 research, which evaluated the enhanced survival rate of liver cancer patients treated with Tecentriq and Avastin.

In November 2020, F. Hoffmann-La Roche Ltd. announced the European Commission's (EU) approval of Tecentriq in conjunction with Avastin for the treatment of liver cancer, intending to expand the product line and increase brand presence in European countries.

In May 2020, the FDA authorized atezolizumab in conjunction with bevacizumab for the initial treatment of liver cancer.

1 INTRODUCTION OF GLOBAL LIVER CANCER TREATMENT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL LIVER CANCER TREATMENT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL LIVER CANCER TREATMENT MARKET, BY PROCESS

5.1 Overview
5.2 Targeted Therapy
5.3 Chemotherapy

6 GLOBAL LIVER CANCER TREATMENT MARKET, BY TYPE

6.1 Overview
6.2 Hepatocellular Carcinoma
6.3 Cholangio Carcinoma

7 GLOBAL LIVER CANCER TREATMENT MARKET, BY END USER

7.1 Overview
7.2 Hospitals
7.3 Clinics

8 GLOBAL LIVER CANCER TREATMENT MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL LIVER CANCER TREATMENT MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Merck & Co. Inc.
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Onyx Pharmaceuticals Inc.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Alnylam Pharmaceuticals, Inc.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Bayer AG
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Jennerex Biotherapeutics Inc.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Celsion Corp
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Celsion Corp
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 ArQule Inc.
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.10 Pfizer Inc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments
10.10 F. Hoffmann-La Roche AG
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments